JP2022501434A5 - - Google Patents
Info
- Publication number
- JP2022501434A5 JP2022501434A5 JP2021539498A JP2021539498A JP2022501434A5 JP 2022501434 A5 JP2022501434 A5 JP 2022501434A5 JP 2021539498 A JP2021539498 A JP 2021539498A JP 2021539498 A JP2021539498 A JP 2021539498A JP 2022501434 A5 JP2022501434 A5 JP 2022501434A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- bcl
- inhibitor
- agent according
- combination agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732816P | 2018-09-18 | 2018-09-18 | |
| US62/732,816 | 2018-09-18 | ||
| PCT/US2019/051764 WO2020061216A1 (en) | 2018-09-18 | 2019-09-18 | Combination therapy for treating blood cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501434A JP2022501434A (ja) | 2022-01-06 |
| JP2022501434A5 true JP2022501434A5 (enExample) | 2022-09-28 |
| JP7460639B2 JP7460639B2 (ja) | 2024-04-02 |
Family
ID=68104787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539498A Active JP7460639B2 (ja) | 2018-09-18 | 2019-09-18 | 血液癌を治療するための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12097194B2 (enExample) |
| EP (1) | EP3852766B1 (enExample) |
| JP (1) | JP7460639B2 (enExample) |
| KR (1) | KR102764125B1 (enExample) |
| CN (1) | CN112739349B (enExample) |
| AU (1) | AU2019343044B2 (enExample) |
| BR (1) | BR112021005054A2 (enExample) |
| CA (1) | CA3110901C (enExample) |
| IL (1) | IL281439B2 (enExample) |
| MX (1) | MX2021003062A (enExample) |
| SG (1) | SG11202101955SA (enExample) |
| TW (1) | TWI824010B (enExample) |
| WO (1) | WO2020061216A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| KR20200108301A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| KR20220098755A (ko) | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
| TW202345813A (zh) | 2022-04-08 | 2023-12-01 | 美商艾科尼佐療法股份有限公司 | 㗁二唑ｈｄａｃ６抑制劑及其用途 |
| WO2025170888A1 (en) * | 2024-02-05 | 2025-08-14 | Signalchem Lifesciences Corporation | A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| PL2387395T3 (pl) | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US10233176B2 (en) * | 2013-11-27 | 2019-03-19 | Signalchem Lifesciences Corporation | Aminopyridine derivatives as TAM family kinase inhibitors |
| IL286427B2 (en) * | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| US20170137426A1 (en) * | 2014-03-28 | 2017-05-18 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
-
2019
- 2019-09-18 SG SG11202101955SA patent/SG11202101955SA/en unknown
- 2019-09-18 EP EP19780095.6A patent/EP3852766B1/en active Active
- 2019-09-18 TW TW108133696A patent/TWI824010B/zh active
- 2019-09-18 KR KR1020217009727A patent/KR102764125B1/ko active Active
- 2019-09-18 JP JP2021539498A patent/JP7460639B2/ja active Active
- 2019-09-18 MX MX2021003062A patent/MX2021003062A/es unknown
- 2019-09-18 AU AU2019343044A patent/AU2019343044B2/en active Active
- 2019-09-18 CN CN201980060442.6A patent/CN112739349B/zh active Active
- 2019-09-18 BR BR112021005054-0A patent/BR112021005054A2/pt unknown
- 2019-09-18 US US17/276,459 patent/US12097194B2/en active Active
- 2019-09-18 WO PCT/US2019/051764 patent/WO2020061216A1/en not_active Ceased
- 2019-09-18 CA CA3110901A patent/CA3110901C/en active Active
- 2019-09-18 IL IL281439A patent/IL281439B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501434A5 (enExample) | ||
| JP2018517686A5 (enExample) | ||
| JP2011219498A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| JPWO2020085493A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2016530213A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JPWO2019013311A5 (enExample) | ||
| AR062526A1 (es) | DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER. | |
| JP2016506961A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2011526917A5 (enExample) | ||
| JP2017531041A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2020534346A5 (enExample) | ||
| JP2022511477A5 (enExample) |